From Global to China, From China to Global: Rethinking Cross-Border Drug Development

Practical perspectives on aligning global and China strategies to unlock cross-border development success.

With the 'two-way integration of the global biopharma industry with China's rapidly evolving ecosystem', companies are now seeking to bring breakthrough global therapies into China and to advance Chinese-originated assets onto the world stage. However, turning this shared ambition into a successful, executable reality remains fraught with complexity.

In this webinar, leading experts from Tigermed, and a pioneering biotech innovator, leverage their front-line experience to deconstruct the critical success factors for the ‘Global-to-China’ and ‘China-to-Global’ pathways.

This webinar goes beyond theory to focus on practical lessons and real-world considerations. Whether you lead a multinational pharmaceutical company's China strategy or are spearheading a local biotech's global ambitions, you will gain invaluable insights into early strategic planning, operational execution, and the power of effective partnerships.

Viewers will learn about:

• How to identify potential pitfalls early and build more resilient and effective development strategies
• Finding your way through the maze of divergent regulatory frameworks, varying clinical practice standards, complex market access systems, and geopolitical risks
• Localizing medical strategy to bring a global asset into China and the importance of early market access integration
• Practical insights for globalizing China-originated assets: navigating global clinical trials, mastering cross-regional collaboration, and proactive risk management
• A case study of a Chinese-US development of a first-in-class cell-converting therapy

download Watch on-demand now